Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Low PE High Dividend Stocks to Buy Right Now. On March 6, Reuters reported that China has approved Pfizer Inc. (NYSE:PFE)’s GLP-1 treatment Xianweiying ...

Pfizer (NYSE:PFE) received full FDA approval for BRAFTOVI (encorafenib) with cetuximab and fluorouracil-based chemotherapy as a first-line treatment for adults with BRAF V600E-mutant metastatic ...

Pfizer received its first obesity drug approval in China for Severwin, opening a new market for the company. The company also reported promising Phase 2 results for tilrekimig, a trispecific antibody ...

Less than two weeks after Pfizer struck a deal with a Chinese drugmaker to gain commercial rights to a GLP-1 drug, the country’s National Medical Products Administration (NMPA) has ...

The U.S. FDA on Tuesday granted traditional approval for a first-line combination regimen involving Braftovi, an oral cancer drug developed by Pfizer (PFE) in partnership with companies such as ...

China has approved a new obesity treatment from Pfizer, heightening competition in a market poised to become even more ...

The clearance in China comes weeks after Pfizer acquired rights to the therapy. Elsewhere, Alnylam is looking for “novel” cardiovascular targets and investors sold off Helus shares.